Tonix Pharmaceuticals Holding Corp. (TNXP): Nasdaq/NYSE listing notice — Tonix Pharmaceuticals receives Nasdaq non-compliance notice and prioritizes CNS pipeline

Tonix Pharmaceuticals Holding Corp.

Received Nasdaq notice on March 31, 2023, for non-compliance with $1 minimum bid price; has 180 days until September 27, 2023 to regain compliance.
Reallocating resources to focus on mid- and late-stage CNS programs: fibromyalgia (TNX-102 SL), depression (TNX-601 ER), migraine (TNX-1900), cocaine intoxication (TNX-1300).
Delaying start of Phase 3 PTSD study in Kenya and discontinuing enrollment in Phase 2 Long COVID study; ~60 patients to be followed, topline data expected Q3 2023.
Cash and cash equivalents approximately $120.2 million as of December 31, 2022; key 2023 milestones include interim Phase 3 RESILIENT data in Q2 and topline data in Q4.
Deprioritizing COVID-19 related programs: anti-COVID antibodies (TNX-3600, -3800, -4100) and vaccines (TNX-1800, -1850); continuing TNX-801 and broad-spectrum antivirals.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tonix Pharmaceuticals Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 31, 2023, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq listing rules, the Company has been provided a period of 180 calendar days, or until Septem

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-23-004420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.